Studying treatment response in nasopharyngeal carcinoma
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study looks at tissue and blood samples from people already treated for nasopharyngeal carcinoma to find markers that predict how well treatment works and to identify new ways to treat the cancer. It may help doctors personalise care in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of nasopharyngeal carcinoma (a type of cancer at the back of the nose/throat).
- You have already received a combination of radiation, chemotherapy and immunotherapy at this hospital.
- You are between 15 and 75 years old.
- You were diagnosed between January 2025 and December 2028 at this hospital.
- You have complete medical records and imaging data.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
This trial tests whether adjusting chemotherapy based on tumor markers (EBV-DNA) and MRI scans can improve outcomes and reduce side effects for people with nasopharyngeal cancer. If you have stage II or III disease, this study might help guide your treatment more precisely.
This trial tests a more precise form of radiation therapy (adaptive radiotherapy) for nasopharyngeal cancer. It is designed for patients who have not yet had any treatment and whose cancer is limited to the head and neck area.
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
This trial tests a new drug (BL-B01D1) given alone or with another drug that helps the immune system fight cancer (called a PD-1 inhibitor). It is for people with newly diagnosed, locally advanced nasopharyngeal cancer. The goal is to see if this combination can shrink or control the cancer better.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.